Salix Pharmaceuticals to buy Santarus for $32/share

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix Pharmaceuticals (SLXP) will acquire Santarus (SNTS) for $32/share, a 38% premium to today's close, valuing the company at ~$2.6B. (PR)